This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
122 |
4. Check minimum number of eventsNone |
122 |
5. Include endpointsNone |
122 |
6. Filter based on genotype QC (FinnGen only) |
118 |
Control definitions (FinnGen only)
- Control exclude
- K11_ENERCOLNONINF
Extra metadata
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- K52
- Name in latin
- Gastroenteritis toxica
Similar endpoints
↥List of similar endpoints to
Toxic colitis
based on the number of shared cases.
Similar with more cases:
- Other noninfective gastroenteritis and colitis
- Noninfective enteritis and colitis
- Gastrointestinal diseases
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 118 | 65 | 53 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | 60.56 | 53.93 | 68.69 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 122
- Matched controls
- 1220
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
K52.1
ICD-10 Finland
Toxic gastroenteritis and colitis
+∞
176.1
122
*
208
Kela drug reimbursment
Ulcerative colitis and Crohn's disease
+∞
24.8
23
*
A07EC02
ATC
mesalazine; oral, rectal
68.5
24.2
27
5
UJF32
NOMESCO Finland
Coloscopy
6.3
23.1
62
172
K52.9
ICD-10 Finland
Noninfective gastroenteritis and colitis, unspecified
88.5
20.4
22
*
UJF45
NOMESCO Finland
Flexible sigmoidoscopy with biopsy
9.1
19.5
27
37
A03FA01
ATC
metoclopramide; systemic, rectal
5.3
18.5
57
173
A04AA02
ATC
granisetron; systemic, transdermal
8.4
18.2
27
40
130
Kela drug reimbursment
Malignant tumour
6.1
15.8
33
70
JN4BD
NOMESCO Finland
Extensive body CT
6.0
15.6
33
71
H02AB02
ATC
dexamethasone; systemic
5.5
15.1
36
86
K51.5
ICD-10 Finland
Left sided colitis
+∞
14.9
14
*
K51.2
ICD-10 Finland
Ulcerative (chronic) proctitis
+∞
14.9
14
*
K51.9
ICD-10 Finland
Ulcerative colitis, unspecified
+∞
14.9
14
*
K51.3
ICD-10 Finland
Ulcerative (chronic) rectosigmoiditis
+∞
14.9
14
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
7.7
14.2
22
34
JN4AD
NOMESCO Finland
Body CT examination
5.8
13.9
30
65
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.5
13.9
32
74
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
4.2
13.5
55
200
UJF30
NOMESCO Finland
Ileoscopy through colon
6.3
12.6
24
46
A04AA01
ATC
ondansetron; systemic, rectal
6.0
12.0
24
48
R11
ICD-10 Finland
Nausea and vomiting
5.5
11.8
26
57
Z51.5
ICD-10 Finland
Palliative care
5.7
11.5
24
50
ZX120
NOMESCO Finland
Intravenous
5.3
11.4
26
59
N02AA05
ATC
oxycodone; systemic
3.9
10.8
43
150
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
3.9
10.3
39
131
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
4.6
10.2
28
74
A07EA02
ATC
hydrocortisone; rectal
44.0
10.2
12
*
JN3AD
NOMESCO Finland
Abdominal CT examination
4.7
10.0
27
70
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
8.3
9.2
20
28
UGC12
NOMESCO Finland
Flexible bronchoscopy
5.6
9.2
19
39
A07EA06
ATC
budesonide; oral, local oral
20.5
9.2
13
7
A02BC02
ATC
pantoprazole; systemic
4.0
9.0
99
633
L04AX01
ATC
azathioprine; systemic
18.0
8.8
13
8
H02AB06
ATC
prednisolone; systemic
3.2
8.7
77
428
L01BC06
ATC
capecitabine; oral
8.2
8.3
18
25
N02AX02
ATC
tramadol; systemic, rectal
3.0
8.2
67
353
P01AB01
ATC
metronidazole; oral, rectal
3.0
8.2
64
329
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
7.9
8.1
18
26
WZC00
NOMESCO Finland
Treatment plan or consultation
2.9
7.8
60
303
K51
ICD-10 Finland
Ulcerative colitis
+∞
7.4
7
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.1
7.1
37
149
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.6
7.1
18
44
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.2
6.5
30
112
JN3BD
NOMESCO Finland
Extensive abdominal CT
3.9
6.5
21
62
B01AB05
ATC
enoxaparin; parenteral
2.7
6.4
50
250
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.6
6.3
54
282
TPX10
NOMESCO Finland
Implantation of vascular injection port
7.4
6.2
14
21
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
9.4
6.2
12
14
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
46
53
13.33
39.40
2.0
1.5
—
—
—
0
0
44
101
6.25
19.74
6.6
4.2
25.23
7.56
ug/l
0.75
38
79
22
20
13.14
12.66
1.2
1.2
—
—
—
0
0
47
168
3.92
11.52
8.4
3.0
0.79
0.83
mmol/l
1.77
47
157
79
399
3.78
11.43
12.9
4.6
32.98
35.90
g/l
3.16
79
381
98
574
4.60
11.33
23.9
9.8
4.19
4.08
e9/l
0.19
92
504
89
509
3.77
10.16
19.8
6.4
10.68
10.85
umol/l
0.07
89
482
79
446
3.19
8.67
13.3
7.2
1.20
1.22
mmol/l
2.00
72
383
74
411
3.03
8.21
10.8
5.9
1.20
1.22
mmol/l
1.87
74
378
21
55
4.40
7.63
1.7
1.3
—
—
—
0
0
65
357
2.76
7.04
4.1
3.0
—
—
—
0
0
33
127
3.19
6.84
10.3
6.6
1.02
1.06
mmol/l
0.27
33
116
49
236
2.80
6.81
2.1
1.9
3.10
2.87
mg/l
0.32
44
207
38
165
2.89
6.35
2.7
1.7
—
—
—
0
0
15
27
6.18
5.91
1.6
1.3
189.10
262.77
ug/g
—
10
12
31
128
2.91
5.62
3.0
2.4
23.74
21.83
%
0.22
25
109
30
127
2.81
5.17
10.2
6.9
104.53
104.28
mmol/l
0.10
30
127
38
186
2.51
4.89
4.3
3.2
42.64
95.22
ng/l
0.63
28
138
48
263
2.36
4.82
3.5
3.8
0.00
0.00
estimate
-0.00
15
92
26
106
2.85
4.78
3.5
2.1
35.46
28.36
u/l
0.56
26
88
68
434
2.28
4.75
23.8
12.1
1.25
1.24
inr
0.01
21
129
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
12
23
5.66
4.59
3.7
2.0
0.25
0.38
u/ml
—
5
11
27
115
2.73
4.56
2.7
1.6
—
—
—
0
0
27
118
2.65
4.33
2.9
1.6
—
—
—
0
0
71
483
2.12
3.99
4.2
3.8
0.00
0.00
estimate
-0.00
15
98
71
484
2.12
3.95
5.6
5.2
0.00
0.00
estimate
-0.00
15
95
7
8
9.19
3.82
2.6
1.4
—
—
—
0
0
33
168
2.32
3.81
4.0
2.5
1.94
2.28
e6/l
0.16
24
89
6
5
12.52
3.80
1.7
2.4
79.33
118.60
%
—
6
5
10
21
5.09
3.64
3.3
1.3
—
—
—
0
0
71
494
2.05
3.63
4.2
3.8
0.00
0.00
estimate
-0.00
16
96
11
26
4.54
3.61
3.4
1.4
—
—
—
0
0
11
26
4.54
3.61
3.4
1.4
—
—
—
0
0
57
371
2.01
3.47
3.8
4.0
—
—
—
0
0
7
10
7.34
3.41
1.3
1.6
305.43
254.20
u/ml
—
7
5
52
331
2.00
3.34
8.8
3.3
2.33
2.35
mmol/l
0.52
47
293
11
29
4.06
3.28
1.2
1.1
—
—
—
0
0
11
29
4.06
3.28
1.2
1.1
—
—
—
0
0
7
11
6.67
3.23
4.1
3.7
2.53
3.95
nmol/l
—
7
11
7
11
6.67
3.23
1.3
1.5
—
—
—
0
0
14
52
2.91
3.00
7.4
4.8
23.43
25.53
mmol/l
1.02
14
52
8
17
4.96
2.97
2.9
1.5
—
—
—
0
0
8
17
4.96
2.97
2.9
1.5
—
—
—
0
0
63
441
1.89
2.97
5.0
2.5
—
—
—
0
0
7
13
5.64
2.91
2.7
1.5
—
—
—
0
0
7
13
5.64
2.91
1.4
1.5
—
—
—
0
0
14
53
2.85
2.91
1.9
1.6
—
—
—
0
0
10
28
3.79
2.85
1.3
1.6
—
—
—
0
0
13
48
2.91
2.82
5.0
3.8
40.64
55.08
%
1.43
13
48
14
54
2.80
2.81
1.1
1.3
—
—
—
0
0
92
740
1.99
2.72
5.6
3.9
13.55
12.39
mm/h
0.33
86
674
8
20
4.20
2.61
4.0
1.3
—
—
—
0
0
6
11
5.67
2.57
2.8
1.5
—
—
—
0
0
6
11
5.67
2.57
2.8
1.5
—
—
—
0
0
5
7
7.38
2.57
1.4
1.3
—
—
—
0
0
32
189
1.94
2.46
4.1
2.3
0.62
0.90
e6/l
0.49
23
108
10
33
3.21
2.42
3.0
2.1
—
—
—
0
0
8
22
3.81
2.41
2.6
1.4
—
—
—
0
0
5
8
6.46
2.39
2.6
2.1
—
—
—
0
0
33
199
1.90
2.38
1.5
1.7
372.00
438.68
pmol/l
1.17
28
165
11
40
2.92
2.34
2.0
1.8
—
—
—
0
0
10
35
3.02
2.27
2.1
1.8
2.55
0.50
g/l
—
10
30
12
48
2.66
2.26
7.7
4.2
24.17
24.61
mmol/l
0.24
12
48
111
980
2.47
2.23
40.9
13.6
24.44
22.56
mg/l
0.29
104
758
5
9
5.74
2.23
3.2
1.3
21.08
12.06
ug/l
—
5
9
5
9
5.74
2.23
2.6
2.0
—
—
—
0
0
5
9
5.74
2.23
2.6
2.0
—
—
—
0
0
5
9
5.74
2.23
2.6
2.0
—
—
—
0
0
10
36
2.93
2.19
1.9
1.8
12.57
9.33
g/l
—
10
31
7
19
3.84
2.18
2.9
1.4
—
—
—
0
0
7
19
3.84
2.18
2.9
1.3
—
—
—
0
0
14
62
2.42
2.17
6.6
3.7
117.93
129.06
g/l
0.96
14
62
13
56
2.48
2.13
2.3
2.8
1.18
1.22
%
0.06
13
56
13
56
2.48
2.13
2.3
2.8
0.69
0.69
%
0.03
13
56
5
10
5.16
2.09
2.6
1.9
—
—
—
0
0
5
10
5.16
2.09
2.6
1.9
—
—
—
0
0
5
10
5.16
2.09
1.6
1.2
—
—
—
0
0
6
15
4.15
2.06
3.5
1.3
—
—
—
0
0
7
21
3.47
1.99
2.1
1.3
—
—
—
0
0
19
100
2.07
1.99
12.6
7.2
—
—
—
0
0
34
219
1.77
1.97
4.4
2.2
—
—
—
0
0
5
11
4.69
1.96
4.0
1.5
—
—
—
0
0
6
16
3.89
1.96
2.3
1.6
—
—
—
0
0
54
396
1.65
1.95
2.1
1.9
95.58
94.47
pmol/l
0.06
33
202
6
17
3.65
1.86
3.0
1.3
—
—
—
0
0
5
12
4.29
1.84
4.6
1.3
—
—
—
0
0
5
12
4.29
1.84
3.4
1.6
—
—
—
0
0
50
382
1.52
1.42
4.3
3.8
17.06
44.81
ng/l
2.01
40
261
6
23
2.69
1.38
3.8
2.0
214.83
173.70
%
—
6
23
5
18
2.85
1.30
1.0
1.3
—
—
—
0
0
5
18
2.85
1.30
8.8
3.1
67.40
63.67
%
—
5
18
5
18
2.85
1.30
3.6
1.4
—
—
—
0
0
8
35
2.37
1.29
1.9
1.9
—
—
—
0
0
8
36
2.31
1.27
2.6
2.0
—
—
—
0
0
97
864
1.60
1.26
46.7
16.7
14.38
14.77
%
0.90
97
852
112
1037
1.98
1.25
43.2
15.9
80.92
78.87
umol/l
0.15
112
1037
5
19
2.70
1.23
2.0
2.1
—
—
—
0
0
26
178
1.59
1.18
1.3
1.5
—
—
—
0
0
109
1006
1.78
1.15
40.5
15.4
139.02
139.81
mmol/l
2.30
109
979
28
198
1.54
1.11
2.0
1.7
1.95
1.25
mg/l
0.43
22
161
109
1010
1.74
1.08
41.1
15.4
3.97
3.97
mmol/l
0.07
109
981
6
27
2.28
0.95
3.8
1.7
77.50
89.81
%
—
6
27
6
28
2.20
0.93
1.0
1.4
—
—
—
0
0
10
58
1.79
0.82
2.2
2.9
4.31
4.45
pmol/l
—
10
52
37
295
1.36
0.78
3.4
3.7
5.05
8.02
mg/mmol
0.60
25
191
99
922
1.39
0.69
5.2
4.5
1.89
1.89
mu/l
0.01
92
840
5
28
1.82
0.67
1.2
1.2
—
—
—
0
0
5
28
1.82
0.67
1.4
1.1
—
—
—
0
0
5
28
1.82
0.67
1.6
1.5
4.00
2.50
e6/l
—
5
22
5
29
1.75
0.64
1.0
1.2
—
—
—
0
0
8
49
1.68
0.63
1.3
2.0
—
—
—
0
0
9
60
1.54
0.56
1.3
2.0
—
—
—
0
0
113
1089
1.51
0.55
55.4
20.3
37.92
40.31
%
3.12
103
1034
93
985
0.77
0.55
4.8
4.9
2.51
2.74
mmol/l
1.50
81
909
69
625
1.24
0.52
3.1
3.0
—
—
—
0
0
98
928
1.28
0.46
34.4
12.5
80.81
81.45
ml/min/173m2
0.10
83
754
113
1091
1.48
0.46
56.3
20.2
127.85
135.57
g/l
5.87
113
1075
91
960
0.80
0.45
4.5
4.4
1.30
1.47
mmol/l
3.65
79
888
87
922
0.80
0.45
4.3
4.0
1.76
1.29
mmol/l
0.67
76
848
5
36
1.41
0.38
1.2
1.4
36.46
22.52
iu/l
—
5
31
13
166
0.76
0.36
1.4
1.3
1.42
9.54
u/ml
—
5
69
25
211
1.23
0.35
1.5
1.3
8.56
0.88
u/ml
—
9
56
13
103
1.29
0.29
6.5
2.9
—
—
—
0
0
26
297
0.84
0.28
5.5
4.5
20.44
21.97
%
0.27
14
136
93
965
0.85
0.27
4.5
4.4
4.42
4.64
mmol/l
0.61
80
901
9
76
1.20
0.25
10.9
4.1
1.22
1.22
mmol/l
—
9
70
0
11
0.00
0.21
0.0
1.0
—
43.33
—
0
6
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
2.2
—
22.20
—
0
5
0
13
0.00
0.21
0.0
1.1
—
—
—
0
0
19
210
0.89
0.13
2.5
2.9
0.84
0.74
ug/l
0.19
14
139
10
111
0.89
0.06
2.5
2.2
—
—
—
0
0
94
950
0.95
0.03
4.9
4.4
6.37
5.92
mmol/l
1.80
85
871
14
146
0.95
0.00
1.4
1.4
—
—
—
0
0
10
102
0.98
0.00
2.1
2.1
—
—
—
0
0
90
904
0.98
0.00
6.5
5.6
41.69
39.60
mmol/mol
1.06
83
842
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
800.43
—
0
7
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
7.86
—
0
5
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
8
81
0.99
-0.00
1.3
2.1
6.45
13.06
nmol/l
—
8
76
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.0
—
13.34
—
0
5
0
7
0.00
-0.00
0.0
1.1
—
13.26
—
0
7
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: COLITTOX – Toxic colitis
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).